Target,Reference Ab,Method,HCDRs Designed,HCDR1,HCDR2,HCDR3,KD (nM),heavy,light,fitness
IL17A,Afasevikumab,Positive Control,,GFTFDDYA,INWSSGGI,ARDIGGFGEFYWNFGL,1.2625000000000002,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGFGEFYWNFGLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,1.2625000000000002
IL17A,Afasevikumab,Inverse Folding,HCDR3,GFTFDDYA,INWSSGGI,ARDIGGEGLYYFVFDL,239.0000000000001,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGEGLYYFVFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,239.0000000000001
IL17A,Afasevikumab,Inverse Folding,HCDR3,GFTFDDYA,INWSSGGI,ARDIGSEGLYYFVFDL,584.0000000000002,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGSEGLYYFVFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,584.0000000000002
IL17A,Afasevikumab,Inverse Folding,HCDR3,GFTFDDYA,INWSSGGI,ARDIGSEGLYYFAFDL,522.9999999999999,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGSEGLYYFAFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,522.9999999999999
IL17A,Afasevikumab,Inverse Folding,HCDR3,GFTFDDYA,INWSSGGI,ARDLGADGLYYFVFDL,533.0000000000001,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDLGADGLYYFVFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,533.0000000000001
IL17A,Afasevikumab,Inverse Folding,HCDR3,GFTFDDYA,INWSSGGI,ARDIGSDGLYYFAFDL,655.0000000000002,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGSDGLYYFAFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,655.0000000000002
IL17A,Afasevikumab,Inverse Folding,HCDR3,GFTFDDYA,INWSSGGI,ARDIGASGLYYFAFDL,446.00000000000006,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGASGLYYFAFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,446.00000000000006
IL17A,Afasevikumab,Inverse Folding,HCDR3,GFTFDDYA,INWSSGGI,ARDVGADGLYYFVFDL,244.0000000000001,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDVGADGLYYFVFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,244.0000000000001
IL17A,Afasevikumab,Inverse Folding,HCDR3,GFTFDDYA,INWSSGGI,ARDVGGDGLYYFVFDL,233.99999999999983,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDVGGDGLYYFVFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,233.99999999999983
IL17A,Afasevikumab,Inverse Folding,HCDR3,GFTFDDYA,INWSSGGI,ARDIGASGLYYFVFDL,596.0000000000001,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGASGLYYFVFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,596.0000000000001
IL17A,Afasevikumab,Inverse Folding,HCDR3,GFTFDDYA,INWSSGGI,ARDIGGDGLYYFVFDL,180.00000000000017,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGDGLYYFVFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,180.00000000000017
IL17A,Afasevikumab,Inverse Folding,HCDR3,GFTFDDYA,INWSSGGI,ARDIGADGLYYFVFDL,280.99999999999994,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGADGLYYFVFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,280.99999999999994
IL17A,Afasevikumab,Inverse Folding,HCDR3,GFTFDDYA,INWSSGGI,ARDIGADGLYYFAFDL,164.00000000000003,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGADGLYYFAFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,164.00000000000003
